从事辅助生殖相关临床工作20余年，临床经验丰富，科研功底扎实，勇于在实践中探索新方法，提出了诸多革新性理念。2012年创造性的将天然孕激素用于卵巢刺激过程中，设计出世界首例基于冷冻胚胎移植的孕激素方案——“安琪坦方案”，目前孕激素方案已得到国内外同行的广泛认可及应用，2019年欧洲人类生殖与胚胎学学会（European Society of Human Reproduction and Embryology, ESHRE）将孕激素方案写入最新版的卵巢刺激指南；在此基础上，进一步研究设计出“晚卵泡期卵巢刺激方案”，无需添加垂体调控剂，进一步拓展了卵巢刺激的灵活性；对来曲唑抵抗的PCOS患者，通过延长来曲唑使用时间，成功诱发排卵，有效降低了多卵泡发育率和OHSS发生风险。目前以第一作者或者通讯作者发表SCI文章18篇，主持课题7项，担任多个SCI期刊审稿人：Frontiers in endocrinology，American journal of reproductive immunology，Gynecological Endocrinology，Medicine，Scientific reports，Human fertility，Journal of Obstetrics and Gynaecology等。
【主持科研课题7项】
(1) 上海市浦东新区科经委民生医疗卫生项，PKJ2024-Y11，多囊卵泡综合征患者卵巢刺激新方案的探索性研究，2024-09至2026-06，10万元，在研，主持
(2) 2026美加墨世界杯官方网站附属上海市第一妇婴保健院院级课题，2023B03，晚卵泡期卵巢刺激方案在多囊卵巢综合征患者体外受精-胚胎移植中的临床应用研究，2024-01至2026-11，50万元，在研，主持
(3) 上海市浦东新区医联体项目，PDYLT2022-22,浦东新区不孕不育诊疗规范建立和专病联盟建设，2022-08至2023-07，9万元，已结题，主持
(4) 2026美加墨世界杯官方网站附属上海市第一妇婴保健院人才项目，2020RC02，晚卵泡期卵巢刺激方案的个体化应用研究，2020-5至2025-04，50万元，已结题，主持
(5) 上海市科委医学引导类科技项目，18411963800，来曲唑在多囊卵巢综合征患者促排卵过程中的个体化应用研究，2018-10至2021-09，20万元，已结题，主持
(6) 上海市科委医学引导类科技项目，17411963700，孕激素方案在多囊卵巢综合征患者控制性卵巢刺激过程中的应用与优化研究，2017-07至2020-06，20万元，已结题，主持
(7) 上海市卫生局，2010276，FSH受体基因Asn680Ser多态性与卵巢反应性关系的研究，2011-01至2012-12，5万元，已结题，主持
【代表性文章】
(1) Zhu X, Lang J, Zhi Y, Wang Q, Fu Y*. A Novel Letrozole Stair-Step Duration Regimen for Ovulation Induction in Women with Polycystic Ovary Syndrome and Letrozole Resistance. Drug Des Devel Ther. 2025 Sep 29;19:8793-8803. (IF=5.1)
(2) Zhu X, Wang Q, Lang J, Zhi Y, Fu Y*, Bao S. Role of follicle-stimulating hormone receptor polymorphism in predicting ovarian response to letrozole in women with polycystic ovary syndrome during ovulation induction. Front Endocrinol (Lausanne). 2025 Jun 19;16:1585655. doi: 10.3389/fendo.2025.1585655 (IF=4.6)
(3) Lang J, Zhu X, Fu Y*. Value of performing initial transvaginal sonography on day 21 after embryo transfer for early diagnosis of ectopic pregnancy: A retrospective cohort study. Int J Gynaecol Obstet. 2025 Jun 18. doi: 10.1002/ijgo.70315 (IF=2.4)
(4) Wang Q, Lang J, Zhi Y, Zhu X, Fu Y*. Predicting factors of ovarian responses in infertile women with polycystic ovary syndrome undergoing IVF/ICSI. J Assist Reprod Genet. 2025 Mar;42(3):865-874. doi: 10.1007/s10815-024-03386-1 (IF=2.7)
(5) Zhu X, Lang J, Wang Q, Fu Y*. Extended versus conventional letrozole regimen in patients with polycystic ovary syndrome undergoing their first ovulation induction cycle: a prospective randomized controlled trial. Hum Reprod Open. 2024;2024(3):hoae046. (IF=11.1)
(6) Zhu X, Fu Y*. Extending letrozole treatment duration is effective in inducing ovulation in women with polycystic ovary syndrome and letrozole resistance. Fertil Steril. 2023;119(1):107-113. (IF=7.0)
(7) Zhu X, Ye J, Fu Y*. Premature ovarian insufficiency patients with viable embryos derived from autologous oocytes through repeated oocyte retrievals could obtain reasonable cumulative pregnancy outcomes following frozen-embryo transfer. Ann Transl Med. 2021;9(7):539. (IF=3.62)
(8) Zhu X, Ye H, Ye J, Fu Y*. Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing in vitro fertilization treatments with frozen-thawed embryo transfer: a prospective randomized controlled trial. Ann Transl Med. 2021;9(5):387. (IF=3.62)
(9) Zhu X, Ye J , Fu Y*. Late follicular phase ovarian stimulation without exogenous pituitary modulators, Front Endocrinol (Lausanne), 2020,11:487. (IF=4.6)
(10)Zhu X, Zhang X, Fu Y*.Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine (Baltimore), 2015, 94(21): e909. (IF=1.4)
